Simon Frantz. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antineoplastic Agents/therapeutic useBenzenesulfonates/pharmacologyBenzenesulfonates/therapeutic useDrug ApprovalDrug DesignEnzyme Inhibitors/pharmacologyNeoplasms/drug therapyNiacinamide/analogs & derivativesPhenylurea CompoundsPhosphotransferases/antagonists & inhibitorsPyridines/pharmacologyPyridines/therapeutic useSorafenibUnited StatesUnited States Food and Drug Administration
Substances: See more » Antineoplastic AgentsBenzenesulfonatesEnzyme InhibitorsPhenylurea CompoundsPyridinesNiacinamideSorafenibPhosphotransferases
Year: 2006 PMID: 16521324 DOI: 10.1038/nrd1972
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN: 1474-1776 Impact factor: 84.694